These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38502075)

  • 21. COVID-19 Vaccine-Associated Uveitis in Patients With a History of Uveitis.
    Kim J; Kwon HY; Ahn SJ
    JAMA Ophthalmol; 2024 Jun; 142(6):522-528. PubMed ID: 38662361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.
    Lopez Bernal J; Andrews N; Gower C; Robertson C; Stowe J; Tessier E; Simmons R; Cottrell S; Roberts R; O'Doherty M; Brown K; Cameron C; Stockton D; McMenamin J; Ramsay M
    BMJ; 2021 May; 373():n1088. PubMed ID: 33985964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records.
    Niesen MJM; Pawlowski C; O'Horo JC; Challener DW; Silvert E; Donadio G; Lenehan PJ; Virk A; Swift MD; Speicher LL; Gordon JE; Geyer HL; Halamka JD; Venkatakrishnan AJ; Soundararajan V; Badley AD
    JAMA Netw Open; 2022 Apr; 5(4):e227038. PubMed ID: 35420661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surveillance for Adverse Events After COVID-19 mRNA Vaccination.
    Klein NP; Lewis N; Goddard K; Fireman B; Zerbo O; Hanson KE; Donahue JG; Kharbanda EO; Naleway A; Nelson JC; Xu S; Yih WK; Glanz JM; Williams JTB; Hambidge SJ; Lewin BJ; Shimabukuro TT; DeStefano F; Weintraub ES
    JAMA; 2021 Oct; 326(14):1390-1399. PubMed ID: 34477808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink.
    Hanson KE; Goddard K; Lewis N; Fireman B; Myers TR; Bakshi N; Weintraub E; Donahue JG; Nelson JC; Xu S; Glanz JM; Williams JTB; Alpern JD; Klein NP
    JAMA Netw Open; 2022 Apr; 5(4):e228879. PubMed ID: 35471572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada.
    Buchan SA; Seo CY; Johnson C; Alley S; Kwong JC; Nasreen S; Calzavara A; Lu D; Harris TM; Yu K; Wilson SE
    JAMA Netw Open; 2022 Jun; 5(6):e2218505. PubMed ID: 35749115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US.
    Hause AM; Zhang B; Yue X; Marquez P; Myers TR; Parker C; Gee J; Su J; Shimabukuro TT; Shay DK
    JAMA Netw Open; 2022 Jul; 5(7):e2222241. PubMed ID: 35838667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases.
    Wong HL; Hu M; Zhou CK; Lloyd PC; Amend KL; Beachler DC; Secora A; McMahill-Walraven CN; Lu Y; Wu Y; Ogilvie RP; Reich C; Djibo DA; Wan Z; Seeger JD; Akhtar S; Jiao Y; Chillarige Y; Do R; Hornberger J; Obidi J; Forshee R; Shoaibi A; Anderson SA
    Lancet; 2022 Jun; 399(10342):2191-2199. PubMed ID: 35691322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of Herpes Zoster Risk Among Recipients of COVID-19 Vaccine.
    Akpandak I; Miller DC; Sun Y; Arnold BF; Kelly JD; Acharya NR
    JAMA Netw Open; 2022 Nov; 5(11):e2242240. PubMed ID: 36383382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines - United States, October 2022.
    Rosenblum HG; Wallace M; Godfrey M; Roper LE; Hall E; Fleming-Dutra KE; Link-Gelles R; Pilishvili T; Williams J; Moulia DL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley MF; Meyer S; Oliver SE; Twentyman E
    MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(45):1436-1441. PubMed ID: 36355612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years.
    Winokur P; Gayed J; Fitz-Patrick D; Thomas SJ; Diya O; Lockhart S; Xu X; Zhang Y; Bangad V; Schwartz HI; Denham D; Cardona JF; Usdan L; Ginis J; Mensa FJ; Zou J; Xie X; Shi PY; Lu C; Buitrago S; Scully IL; Cooper D; Koury K; Jansen KU; Türeci Ö; Şahin U; Swanson KA; Gruber WC; Kitchin N;
    N Engl J Med; 2023 Jan; 388(3):214-227. PubMed ID: 36652353
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interim Recommendations for Use of Bivalent mRNA COVID-19 Vaccines for Persons Aged ≥6 Months - United States, April 2023.
    Moulia DL; Wallace M; Roper LE; Godfrey M; Rosenblum HG; Link-Gelles R; Britton A; Daley MF; Meyer S; Fleming-Dutra KE; Oliver SE; Twentyman E
    MMWR Morb Mortal Wkly Rep; 2023 Jun; 72(24):657-662. PubMed ID: 37319020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety signal identification for COVID-19 bivalent booster vaccination using tree-based scan statistics in the Vaccine Safety Datalink.
    Katherine Yih W; Daley MF; Duffy J; Fireman B; McClure DL; Nelson JC; Qian L; Smith N; Vazquez-Benitez G; Weintraub E; Williams JTB; Xu S; Maro JC
    Vaccine; 2023 Aug; 41(36):5265-5270. PubMed ID: 37479610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years.
    Feldstein LR; Britton A; Grant L; Wiegand R; Ruffin J; Babu TM; Briggs Hagen M; Burgess JL; Caban-Martinez AJ; Chu HY; Ellingson KD; Englund JA; Hegmann KT; Jeddy Z; Lauring AS; Lutrick K; Martin ET; Mathenge C; Meece J; Midgley CM; Monto AS; Newes-Adeyi G; Odame-Bamfo L; Olsho LEW; Phillips AL; Rai RP; Saydah S; Smith N; Steinhardt L; Tyner H; Vandermeer M; Vaughan M; Yoon SK; Gaglani M; Naleway AL
    JAMA; 2024 Feb; 331(5):408-416. PubMed ID: 38319331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study.
    Hippisley-Cox J; Patone M; Mei XW; Saatci D; Dixon S; Khunti K; Zaccardi F; Watkinson P; Shankar-Hari M; Doidge J; Harrison DA; Griffin SJ; Sheikh A; Coupland CAC
    BMJ; 2021 Aug; 374():n1931. PubMed ID: 34446426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccine-Associated Uveitis after COVID-19 Vaccination: Vaccine Adverse Event Reporting System Database Analysis.
    Singh RB; Parmar UPS; Kahale F; Agarwal A; Tsui E
    Ophthalmology; 2023 Feb; 130(2):179-186. PubMed ID: 36055601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of potential adverse events following the 2022-2023 seasonal influenza vaccines among U.S. adults aged 65 years and older.
    Shi XC; Gruber JF; Ondari M; Lloyd PC; Freyria Duenas P; Clarke TC; Nadimpalli G; Cho S; Feinberg L; Hu M; Chillarige Y; Kelman JA; Forshee RA; Anderson SA; Shoaibi A
    Vaccine; 2024 May; 42(15):3486-3492. PubMed ID: 38704258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination.
    Gorochov G; Ropers J; Launay O; Dorgham K; da Mata-Jardin O; Lebbah S; Durier C; Bauer R; Radenne A; Desaint C; Vieillard LV; Rekacewicz C; Lachatre M; Parfait B; Batteux F; Hupé P; Ninove L; Lefebvre M; Conrad A; Dussol B; Maakaroun-Vermesse Z; Melica G; Nicolas JF; Verdon R; Kiladjian JJ; Loubet P; Schmidt-Mutter C; Dualé C; Ansart S; Botelho-Nevers E; Lelièvre JD; de Lamballerie X; Kieny MP; Tartour E; Paul S
    JAMA Netw Open; 2024 Apr; 7(4):e248051. PubMed ID: 38652471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
    Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
    Oda Y; Kumagai Y; Kanai M; Iwama Y; Okura I; Minamida T; Yagi Y; Kurosawa T; Greener B; Zhang Y; Walson JL
    Lancet Infect Dis; 2024 Apr; 24(4):351-360. PubMed ID: 38141632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.